Xiang Jiang Xu, Phyo Kyaw Myint, Shaun Wen Huey Lee, Kalavathy Ramasamy, Siong Meng Lim, Abu Bakar Abdul Majeed, Yuet Yen Wong, Sumaiyah Mat, Nor Izzati Saedon, Hazlina Mahadzir, Kejal Hasmukharay, Maw Pin Tan
{"title":"The usage of anticholinergic medications in a low- and middle-income country: a longitudinal comparison of 2013–15 and 2020–22 datasets","authors":"Xiang Jiang Xu, Phyo Kyaw Myint, Shaun Wen Huey Lee, Kalavathy Ramasamy, Siong Meng Lim, Abu Bakar Abdul Majeed, Yuet Yen Wong, Sumaiyah Mat, Nor Izzati Saedon, Hazlina Mahadzir, Kejal Hasmukharay, Maw Pin Tan","doi":"10.1007/s11096-024-01791-1","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>While the effects of anticholinergic drug use have been increasingly highlighted, trends in anticholinergic use remain poorly understood.</p><h3 data-test=\"abstract-sub-heading\">Aim</h3><p>To determine the changes in frequency and pattern of anticholinergic drug use within a low- and middle-income country.</p><h3 data-test=\"abstract-sub-heading\">Method</h3><p>Comparisons were made between population-based datasets collected from Malaysian residents aged 55 years and older in 2013–15 and 2020–22. Anticholinergic exposure was determined using the anticholinergic cognitive burden (ACB) tool. Drugs with ACB were categorised according to the Anatomical Therapeutic Chemical (ATC) classification.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total number of 5707 medications were recorded from the 1616 participants included in the 2013–15 dataset. A total number of 6175 medications were recorded from 2733 participants in 2020–22. Two hundred and ninety-three (18.1%) and 280 (10.2%) participants consumed <span>\\(\\ge 1\\)</span> medication with ACB <span>\\(\\ge 1\\)</span> in 2013–15 and 2020–22 respectively. The use of nervous system drugs with ACB had increased (27 (0.47%) versus 39 (0.63%). The use of ACB drugs in the cardiovascular (224 (3.9%) versus 215 (3.4%)) and alimentary tract and metabolism (30 (0.52%) versus 4 (0.06%)) classes had reduced over time. Participants in 2020–22 were significantly less likely than those in 2013–15 to have total ACB = 1 − 2 (odds ratio [95% confidence interval] = 0.473[0.385–0.581]) and ACB <span>\\(\\ge\\)</span> 3 (0.251[0.137 − 0.460]) compared to ACB = 0 after adjustment for potential confounders (<i>p</i> < 0.001).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Although anticholinergic exposure has decreased over time, the use of medications with anticholinergic effects in the nervous system class has risen. This increase is attributable to antipsychotic use, which is of concern due to potential cardiovascular complications, and deserves further evaluation.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11096-024-01791-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
While the effects of anticholinergic drug use have been increasingly highlighted, trends in anticholinergic use remain poorly understood.
Aim
To determine the changes in frequency and pattern of anticholinergic drug use within a low- and middle-income country.
Method
Comparisons were made between population-based datasets collected from Malaysian residents aged 55 years and older in 2013–15 and 2020–22. Anticholinergic exposure was determined using the anticholinergic cognitive burden (ACB) tool. Drugs with ACB were categorised according to the Anatomical Therapeutic Chemical (ATC) classification.
Results
A total number of 5707 medications were recorded from the 1616 participants included in the 2013–15 dataset. A total number of 6175 medications were recorded from 2733 participants in 2020–22. Two hundred and ninety-three (18.1%) and 280 (10.2%) participants consumed \(\ge 1\) medication with ACB \(\ge 1\) in 2013–15 and 2020–22 respectively. The use of nervous system drugs with ACB had increased (27 (0.47%) versus 39 (0.63%). The use of ACB drugs in the cardiovascular (224 (3.9%) versus 215 (3.4%)) and alimentary tract and metabolism (30 (0.52%) versus 4 (0.06%)) classes had reduced over time. Participants in 2020–22 were significantly less likely than those in 2013–15 to have total ACB = 1 − 2 (odds ratio [95% confidence interval] = 0.473[0.385–0.581]) and ACB \(\ge\) 3 (0.251[0.137 − 0.460]) compared to ACB = 0 after adjustment for potential confounders (p < 0.001).
Conclusion
Although anticholinergic exposure has decreased over time, the use of medications with anticholinergic effects in the nervous system class has risen. This increase is attributable to antipsychotic use, which is of concern due to potential cardiovascular complications, and deserves further evaluation.
期刊介绍:
The International Journal of Clinical Pharmacy (IJCP) offers a platform for articles on research in Clinical Pharmacy, Pharmaceutical Care and related practice-oriented subjects in the pharmaceutical sciences.
IJCP is a bi-monthly, international, peer-reviewed journal that publishes original research data, new ideas and discussions on pharmacotherapy and outcome research, clinical pharmacy, pharmacoepidemiology, pharmacoeconomics, the clinical use of medicines, medical devices and laboratory tests, information on medicines and medical devices information, pharmacy services research, medication management, other clinical aspects of pharmacy.
IJCP publishes original Research articles, Review articles , Short research reports, Commentaries, book reviews, and Letters to the Editor.
International Journal of Clinical Pharmacy is affiliated with the European Society of Clinical Pharmacy (ESCP). ESCP promotes practice and research in Clinical Pharmacy, especially in Europe. The general aim of the society is to advance education, practice and research in Clinical Pharmacy .
Until 2010 the journal was called Pharmacy World & Science.